848440-15-3

Basic information

• Product Name: 6,7-Quinazolinediol, 4-[(3-chloro-2-fluorophenyl)amino]-
• CAS NO: 848440-15-3
• Molecular Formula: C14H9ClFN3O2
• Molecular Weight: 305.696
• Mol File: 848440-15-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 6,7-Quinazolinediol, 4-[(3-chloro-2-fluorophenyl)amino]-(CAS DataBase Reference)
• NIST Chemistry Reference: 6,7-Quinazolinediol, 4-[(3-chloro-2-fluorophenyl)amino]-(848440-15-3)
• EPA Substance Registry System: 6,7-Quinazolinediol, 4-[(3-chloro-2-fluorophenyl)amino]-(848440-15-3)

Safety Data

• Hazardous Substances Data: 848440-15-3(Hazardous Substances Data)

Upstream product

• 1145671-36-8 4-chloro-6,7-dihydroxyquinazoline 
• 2106-04-9 3-chloro-2-fluoroaniline 
• 612501-52-7 4-(3-chloro-2-fluoroanilino)-6-hydroxy-7-methoxyquinazoline 
• 179688-52-9 6-hydroxy-7-methoxyquinazolin-4(3H)-one 
• 13794-72-4 3H-6,7-dimethoxyquinazolin-4-one 
• 230955-75-6 6-acetoxy-4-chloro-7-methoxyquinazoline 
• 740081-22-5 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl acetate 

Downstream Products

• 870152-45-7 2,2-dimethyl-propionic acid 4-(3-chloro-2-fluoro-phenylamino)-7-(2-methoxy-ethoxy)-quinazolin-6-yl ester 
• 870152-46-8 2,2-dimethyl-propionic acid 4-(3-chloro-2-fluoro-phenylamino)-7-(2-methylsulfanyl-ethoxy)-quinazolin-6-yl ester 
• 870152-47-9 2,2-dimethyl-propionic acid 4-(3-chloro-2-fluoro-phenylamino)-7-isopropoxy-quinazolin-6-yl ester 
• 870152-48-0 4-(3-chloro-2-fluoro-phenylamino)-7-(2-methoxy-ethoxy)-quinazolin-6-ol 
• 870152-49-1 4-(3-chloro-2-fluoro-phenylamino)-7-(2-methylsulfanyl-ethoxy)-quinazolin-6-ol 
• 870152-50-4 4-(3-chloro-2-fluoro-phenylamino)-7-isopropoxy-quinazolin-6-ol 
• 848440-16-4 acetic acid 4-(3-chloro-2-fluoro-phenylamino)-7-hydroxy-quinazolin-6-yl ester 
• 870152-43-5 2,2-dimethyl-propionic acid 4-(3-chloro-2-fluoro-phenylamino)-7-hydroxy-quinazolin-6-yl ester 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR TREATING CANCER

The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating Glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating Glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS

A novel class of fluorinated derivatives of Formula I have been prepared and found to be useful in the treatment of cancers and other EGFR related disorders.

QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS

The invention concerns quinazoline derivatives of the Formula (I); wherein each of R1, R2, W, X1, X2, Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions co